# EDGAR Filing Document

**Accession Number:** 0001420800
**File Stem:** 0001209191-23-014360
**Filing Date:** 2023-3
**Character Count:** 6916
**Document Hash:** 6dd82fbb25833925beccdd2a16b33aad
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001209191-23-014360.hdr.sgml**: 20230301

**ACCESSION NUMBER**: 0001209191-23-014360

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230227

**FILED AS OF DATE**: 20230301

**DATE AS OF CHANGE**: 20230301

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Lang Patricia A
- **CENTRAL INDEX KEY:** 0001739135

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-34045
- **FILM NUMBER:** 23695962

**MAIL ADDRESS:**
- **STREET 1:** C/O DIEBOLD NIXDORF, INCORPORATED
- **STREET 2:** 5995 MAYFAIR ROAD
- **CITY:** NORTH CANTON
- **STATE:** OH
- **ZIP:** 44720
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Enovis CORP
- **CENTRAL INDEX KEY:** 0001420800
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **IRS NUMBER:** 541887631
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 2711 CENTERVILLE ROAD
- **STREET 2:** SUITE 400
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19808
- **BUSINESS PHONE:** (302) 252-9160

**MAIL ADDRESS:**
- **STREET 1:** 2711 CENTERVILLE ROAD
- **STREET 2:** SUITE 400
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19808

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Colfax CORP
- **DATE OF NAME CHANGE:** 20071210

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Lang Patricia A<br><sub>(Last) (First) (Middle)</sub><br>2711 CENTERVILLE ROAD<br>SUITE 400<br><sub>(Street)</sub><br>WILMINGTON, DE 19808<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-02-27 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_SVP, Chief HR Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Enovis CORP [ ENOV ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common stock, par value $0.001 | 2023-02-27 |  | A<sup>(1)</sup> |  | 3913<sup>(1)</sup> | A | $0.00 | 18329 | D |  |
| Common stock, par value $0.001 | 2023-02-27 |  | S<sup>(2)</sup> |  | 1963<sup>(2)</sup> | D | $56.09 | 16366 | D |  |
| Common stock, par value $0.001 | 2023-02-28 |  | A<sup>(3)</sup> |  | 4032<sup>(3)</sup> | A | $0.00 | 20398 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Employee Stock Option (right to buy) | $57.62 | 2023-02-28 |  | A |  | 9560 |  | <sup>(4)</sup> | 2030-02-27 | Common stock, par value $0.001 | 9560 | $0.00 | 9560 | D |  |

---

### Footnotes:

(1) Reflects the certification of the performance criteria for PRSUs previously awarded in 2020.  For more details on the PRSUs, please refer to the "Outstanding Equity Awards at 2021 Fiscal Year-End" table on page 45 of Enovis Corporation's proxy statement as filed with the Securities and Exchange Commission on April 28, 2022.

(2) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person to meet tax withholding obligations relating to the vesting and deliver of certain restricted stock units and performance-based restricted units.

(3) This award represents restricted stock units that vest in three equal annual installments beginning on the first anniversary of the grant date.

(4) The option vests in three equal annual installments beginning on the first anniversary of the grant date.

**Signature:** /s/ Brian P. Hanigan, attorney-in-fact  
**Date:** 2023-03-01

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**